Gibson Dunn has advised BVP Forge and Lightning Step, and Pillsbury Winthrop has advised Sunwave Health. Sunwave Health and Lightning Step Technologies have merged to form...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP has advised X4 Pharmaceuticals, and Freshfields US LLP has advised the underwriters. Dechert LLP has served as special counsel for X4...
You must be a Standard 1 Year member to access this content.
Gibson Dunn has advised Serent Capital and CallRevu, and Kirkland & Ellis has advised Astira Capital Partners. Serent Capital has announced the acquisition of its portfolio...
You must be a Standard 1 Year member to access this content.
Gibson Dunn and Goodwin Procter has advised Dianthus Therapeutics, Inc., while Cooley has represented the underwriters. Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on antibody...
You must be a Standard 1 Year member to access this content.
Gibson Dunn & Crutche, Thomson Geer and Herbert Smith Freehills advised Piedmont Lithium Inc. on the transaction, while Herbert Smith Freehills, Baker Botts and McCarthy Tétrault...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher advised 89bio, Inc. on the offering, and Cooley advised the underwriters. 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company, announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher represented Apogee Therapeutics, Inc. in the offering, and Cooley represented the underwriters. Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company, announced the...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP advised 89bio, Inc. on its upsized public offering. 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and...
You must be a Standard 1 Year member to access this content.
